335099
Glycemic Control Among Private-Insured Patients with Diabetes in a Primary Care Setting: Characteristics and associated factors
Background: Effective diabetic management, including glycemic control, reduces complications from the disease.
Methods: A cross sectional study was conducted among a cohort of 2711 adults with Diabetes Mellitus (ICD9 code of 250.XX) who received care between 2011 and 2014 in a primary care practice. Patient characteristics and risk factors were identified from electronic health records.
Results: Demographics of the patient population include 54.9% male, 45.1% female, 45.9% white, 33.9% black, 26.7% had commercial insurance, and 26.7 had Medicare. About 48.2% were over 60 years old and 90% were overweight or obese. Only 54.1% had good glycemic control (HbA1c <7%), while 19.7% of patients had HbA1c levels of 7-8%, 15.4% of 8-9%, and 10.8% had levels higher than 9%. Patients aged 60 and older, male, white, and lower BMI showed lower HbA1c levels. Longer time since diagnosis was not associated with lower HbA1c. There were big variations for the frequency of HbA1c testing among the patients who had diabetes. Additional multivariable linear and regression models will be perform for further analysis.
Conclusion: The proportion of patients with poor glycemic control was high, which was comparable to that reported in the literature. These results underscore the complexity of primary care management of patients with diabetes and suggest the need for further improvement.
Learning Areas:
Administration, management, leadershipChronic disease management and prevention
Communication and informatics
Learning Objectives:
Describe the level of glycemic control for diabetes patients under primary care setting and identify the risk factors
Keyword(s): Diabetes, Medical Care
Organization/institution whose products or services will be discussed: none
Qualified on the content I am responsible for because: I designed and implemented this research.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.